Related Experiment Video
Updated: Jun 23, 2026
07:28
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Symbicort: a pharmacoeconomic review
1David.Halpin@rdeft.nhs.uk
Journal of Medical Economics
|May 20, 2009
Summary
Symbicort, a budesonide and formoterol inhaler, is cost-effective for asthma and COPD. Its use, especially the SMART (Symbicort Maintenance And Reliever Therapy) approach, reduces costs and improves symptom control compared to other treatments.
Area of Science:
- Pharmacoeconomics
- Respiratory Medicine
- Health Economics
Background:
- Symbicort, a combination inhaler containing budesonide and formoterol, is utilized for managing asthma and chronic obstructive pulmonary disease (COPD).
- It offers various therapeutic approaches in asthma, including fixed-dose maintenance, adjustable-dose maintenance, and the Symbicort Maintenance And Reliever Therapy (SMART) regimen.
Purpose of the Study:
- To systematically review the published pharmacoeconomic evidence for Symbicort in the treatment of asthma and COPD.
- To evaluate the cost-effectiveness of different Symbicort dosing strategies and compare them with alternative therapies.
Main Methods:
- A comprehensive literature search was conducted using PubMed to identify relevant pharmacoeconomic studies on Symbicort.
- Additional studies were sourced from reference lists of retrieved papers and relevant journal tables of contents.
- The review included 13 studies on Symbicort in asthma and 2 studies in COPD.
Main Results:
- Symbicort demonstrated lower total costs compared to using separate inhalers for budesonide and formoterol.
- Adjustable dosing with Symbicort resulted in better asthma control with less medication and lower costs than fixed dosing or fluticasone/salmeterol.
- SMART therapy improved asthma control, reduced exacerbations, and lowered direct and indirect costs compared to fixed maintenance therapies.
- In COPD, Symbicort provided clinical benefits over monocomponent therapies at minimal additional cost.
Conclusions:
- Symbicort is a cost-effective treatment option for both asthma and COPD.
- The SMART regimen offers significant advantages in terms of clinical outcomes and cost reduction for asthma management.
- Symbicort presents a favorable economic profile in COPD, offering clinical benefits with comparable or slightly higher costs.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).